Vor Bio (NASDAQ:VOR) has secured a $75 million private placement with TCGX, a transaction executed on March 27, 2026, that significantly bolsters the company's balance sheet.
Announced concurrently with its fourth-quarter and full-year 2025 financial results, the new capital extends the clinical-stage company's operational runway into early 2029.
Factoring in the recent financing, Vor Bio reported pro-forma cash and investments totaling $530.2 million as of December 31, 2025.
On the clinical front, the company continues to progress its late-stage pipeline, marking a key operational milestone by dosing the first patient in its global Phase 3 UPSTREAM SjD trial.
Market focus will now begin shifting toward the first half of 2027, when Vor Bio expects to release topline data for its generalized myasthenia gravis (gMG) program.
Meanwhile, the company's 2025 financial figures reflected an acceleration in clinical development costs.
Research and development expenses surged to $321.5 million for the year, representing a $228.2 million increase year-over-year.
General and administrative expenses for 2025 were reported at $50.1 million.
While Vor Bio posted a full-year net loss of $696 million, the fourth quarter yielded a net income of $1.72 billion.
This Q4 profitability was strictly driven by non-cash, fair-value gains associated with the company's outstanding warrants, rather than operating revenue.